Application of RING1 in inhibiting esophageal squamous cell carcinoma metastasis through ubiquitination and degradation of Integrin α5
By enhancing the E3 ubiquitin ligase activity of RING1, promoting the K11 ubiquitination and degradation of Integrin α5, and inhibiting the FAK signaling pathway, the unresolved biological function of RING1 in esophageal squamous cell carcinoma metastasis was resolved, achieving effective inhibition of ESCC cell migration and metastasis, and providing a new treatment approach.
CN122440831APending Publication Date: 2026-07-24YANGZHOU FIRST PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- CN202610761722.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-05-29
- Publication Date
- 2026-07-24
Smart Images
Figure CN122440831A_ABST
Abstract
The application belongs to the technical field of biological pharmacy, discloses application of RING1 in inhibition of esophageal squamous cell carcinoma metastasis through ubiquitination degradation of Integrin alpha 5, and provides application of a RING1 activator in preparation of a drug for treating metastatic esophageal squamous cell carcinoma. The application systematically evaluates the inhibiting effect of RING1 on esophageal squamous cell carcinoma metastasis through in-vitro cell experiments and a mouse in-vivo metastasis model; the results show that RING1 inhibits the activation of the FAK signal pathway by mediating K11 type ubiquitination degradation of Integrin alpha 5, and then inhibits the adhesion, migration ability and in-vivo metastasis ability of ESCC cells.
Need to check novelty before this filing date? Find Prior Art